US Stock MarketDetailed Quotes
REGN Regeneron Pharmaceuticals
- 731.300
- -9.670-1.31%
Close Dec 13 16:00 ET
- 731.300
- 0.0000.00%
Post 20:02 ET
80.36BMarket Cap18.09P/E (TTM)
740.170High728.680Low696.99KVolume738.450Open740.970Pre Close510.66MTurnover0.66%Turnover Ratio21.03P/E (Static)109.89MShares1211.20052wk High2.74P/B77.08BFloat Cap728.68052wk Low--Dividend TTM105.41MShs Float1211.200Historical High--Div YieldTTM1.55%Amplitude4.610Historical Low732.664Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Regeneron Pharmaceuticals Stock Forum
$Hershey (HSY.US)$ $Celsius Holdings (CELH.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $Yelp Inc (YELP.US)$ $Innovative Industrial Properties Inc (IIPR.US)$
Crypto: $Coinbase (COIN.US)$ $GEMINI GROUP GLOBAL CORP (GMNI.US)$ $Riot Platforms (RIOT.US)$
Financials: $JPMorgan (JPM.US)$ $Morgan Stanley (MS.US)$ $Wells Fargo & Co (WFC.US)$
Traditional Energy: $Exxon Mobil (XOM.US)$ $Chevron (CVX.US)$ $ConocoPhillips (COP.US)$
Biotechnology: $Amgen (AMGN.US)$ $Gilead Sciences (GILD.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Biogen (BIIB.US)$ $Regeneron Pharmaceuticals (REGN.US)$
...
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...
Day 1 passed quickly, when I first looked at the US market, it was in the reds. I was at a lost to choose what stocks or ETFs to buy.
I first placed an order in $SPDR S&P 500 ETF (SPY.US)$ to act as a buffer, and managed to get it at the price I wanted.
I then found $Regeneron Pharmaceuticals (REGN.US)$ was dropping quite a bit s...
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
In 2024, biotech stocks had a slow start, with the S&P Biotechnology Select Industry Index returning just under 4% in the first six months, compared to...
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...
No comment yet